Three recombinantly expressed apple tyrosinases suggest the amino acids responsible for mono- versus diphenolase activity in plant polyphenol oxidases
Lilly recently reported topline results from the ATTAIN-1 phase-3 trial evaluating orforglipron, a once-daily oral glucagon-like-peptide-1 (GLP-1) receptor agonist for adults with obesity or overweight without diabetes
These sources were used to collect prescription statistics, regulatory approval data, clinical safety studies, epidemiological trends, and competitive landscape analysis for short-acting GLP-1 agonists, long-acting GLP-1 agonists, dual-action therapies, and emerging oral/inhalation formulations
Its approved for use in adults with type 2 diabetes to: help manage blood sugar levels, along with diet and exercise help lower the risk of heart problems, when used in people with heart disease or risk factors for heart disease But there may be situations where your doctor may prescribe Trulicity off-label for weight loss